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Polymorphisms of the IL12B and IL23R Genes Are
Associated with Psoriasis
Rajan P. Nair1,9, Andreas Ruether2,9, Philip E. Stuart1,9, Stefan Jenisch3, Trilokraj Tejasvi1,
Ravi Hiremagalore1, Stefan Schreiber2,4, Dieter Kabelitz3, Henry W. Lim5, John J. Voorhees1,
Enno Christophers6, James T. Elder1,7,8 and Michael Weichenthal6
Psoriasis is a common inflammatory and hyperproliferative skin disease with a multifactorial genetic basis. A
recent study reported that psoriasis was associated with the IL12B haplotype rs3212227 (30-untranslated
region)–rs6887695 (60 kb, 50) and the IL23R haplotype rs7530511 (L310P)–rs11209026 (Q381R). We examined these
four single-nucleotide polymorphisms (SNPs) for association with psoriasis in two groups of North American
and German Caucasians: (1) 1,810 cases and 2,522 controls; and (2) 509 pedigrees. Both IL12B markers showed
highly significant association with psoriasis in the case–control (rs3212227, odds ratio (OR)¼ 1.62, P¼ 1.7 1015;
rs6887695, OR¼ 1.49, P¼ 2.7 1015) and in the family-based analysis (rs3212227, P¼ 2.2 103; rs6887695,
P¼ 1.7 103). The IL23R SNPs also showed significant association in the cases and controls (rs7530511,
OR¼ 1.22, P¼ 3.9 103; rs11209026, OR¼ 1.40, P¼ 3.8 104). For both genes, common risk haplotypes were
identified whose statistical significance approached (IL23R) or exceeded (IL12B) genome-wide criteria. We
found no statistical evidence for interactions of these haplotypes with HLA-Cw6. Our results confirm
associations between IL12B and IL23R and psoriasis in Caucasians, and provide a genetic basis for the clinical
association between psoriasis and Crohn’s disease.
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INTRODUCTION
Psoriasis is a common inflammatory skin disease character-
ized by keratinocyte hyperproliferation and increased blood
flow stimulated by tissue-resident immune cells responding to
a markedly altered profile of cutaneous cytokine expression
(Boyman et al., 2007; Lowes et al., 2007). Recently, several
lines of evidence have converged to suggest that IL-23 might
play a particularly important role in this process, not only in
psoriasis but also in Crohn’s disease and a variety of other
inflammatory disorders (Kader et al., 2005; Yen et al., 2006;
Nickoloff, 2007). Both psoriasis and Crohn’s disease have a
strong albeit multifactorial genetic basis, and both disorders
respond well to tumor necrosis-a blockers (Najarian and
Gottlieb, 2003). Suggestive of a genetic link, psoriasis is
approximately five times more common in Crohn’s disease
patients than in controls (Lee et al., 1990). The CARD15
gene has been convincingly associated with Crohn’s disease
(Hampe et al., 2001; Hugot, 2006), and in one study, with
psoriatic arthritis (Rahman et al., 2003). However, this
association has not been replicated subsequently for either
psoriasis or psoriatic arthritis, suggesting that other genes
might be responsible for the observed clinical association
(Nair et al., 2001; Giardina et al., 2004; Lascorz et al., 2005;
Jenisch et al., 2006). Recently, a genome-wide association
scan identified a highly significant association between
Crohn’s disease and a single-nucleotide polymorphism
(SNP) in the coding region of the IL23R gene (rs11209026,
c.1142G4A, p.Q381R) (Duerr et al., 2006). This finding
prompted us to search for a similar association between this
SNP and psoriasis. While our studies were underway, Cargill
et al. (2007) reported a gene-centric genome-wide associa-
tion scan in psoriasis, which identified significant associa-
tions with SNPs in the IL12B gene (which encodes the p40
subunit common to both IL-12 and IL-23), as well as with
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rs1129026 in IL23R. In those studies, psoriasis was associated
with a common allele (A–G) of the IL12B haplotype
rs3212227 (30-untranslated region)–rs6887695 (60 kb, 50),
and with a common allele (C–G) of the IL23R haplotype
rs7530511 (L310P)–rs11209026 (Q381R). In fact, an earlier
study of IL12B as a candidate gene for psoriasis in a Japanese
population had already identified a nominally significant
association with rs3212227 (Tsunemi et al., 2002). Very
recently, reports of associations between psoriasis and SNPs
in the IL12B and/or IL23R genes have emerged from Taiwan
and Great Britain (Capon et al., 2007; Chang et al., 2007).
In an effort to confirm these observations, we expanded
our initial study of rs11209026 in IL23R to include the
following three additional SNPs: rs7530511 in IL23R and
rs3212227, and rs6887695 in IL12B. We typed these four
SNPs in a collection of North American and German
Caucasians consisting of 1,810 cases, 2,522 controls, and
509 pedigrees of various structures (Table 1). We found
highly significant associations between psoriasis and both of
these genes, with common haplotypes conferring risk in each
case as previously reported (Cargill et al., 2007). Although we
found no statistical evidence for epistasis between either
IL12B or IL23R and HLA-Cw6, our analysis revealed major
increases in risks between the highest and lowest two-locus
risk genotype classes (25-fold for IL12B and 16-fold for
IL23R). Our results confirm that psoriasis is associated with
IL12B and IL23R in a large independent Caucasian sample,
and demonstrate that their contribution to psoriasis suscepti-
bility is statistically independent of HLA-Cw6.
RESULTS
Allele frequency analysis
There were no significant deviations from Hardy–Weinberg
equilibrium for any of the four IL23R and IL12B SNPs in either
the Kiel or Michigan controls (nominal P¼ 0. 069–1.00 for 8
tests). Differences in minor-allele frequency (MAF) between
Kiel and Michigan controls were substantial for both IL12B
SNPs and the IL23R SNP rs7530511 (absolute difference in
MAF¼ 3–3.5%, P¼0.0020–0.010). Because these differences
in control MAFs between samples are 40–180% as large as the
difference in MAF between cases and controls within each
sample, simple pooling of data to achieve a combined
analysis was avoided because this would unduly bias case–-
control association tests. Interestingly, absolute differences in
MAFs between cases of the Kiel and Michigan samples
(0.1–1.3%) were much smaller than those for controls and
non-significant for all SNPs.
Modeling of case–control association
All results reported here are for an ordinal linear trend model,
because in every instance, goodness-of-fit tests showed that
this model fit the data as well as the lesser-powered nominal
model (nominal P¼ 0.10–1 for 48 tests). Under the linear
trend model, risk is assumed to act in a multiplicative (log-
additive) manner. Consequently, the odds ratios (ORs)
reported here simultaneously estimate the odds of disease
for risk allele homozygotes compared with heterozygotes,
and for heterozygotes compared with non-carriers. The OR
for risk allele homozygotes versus non-carriers is then
obtained by squaring this OR. For all analyses, a test of the
null hypothesis of homogeneous association across samples
was non-significant (nominal P¼0.11–0.89 for 28 tests), so it
is reasonable to add a stratum variable to the regression
model for a combined analysis of association in both
samples. Permutational and asymptotic P-values for tests of
association were similar in all cases; asymptotic P-values are
reported here.
Single-marker case–control association
Results obtained for single SNP analysis in the case–control
sample are presented in Table 2. The IL12B SNPs rs3212227
and rs6887695 were very strongly associated with psoriasis in
Table 1. Sample sizes for analyses of this study
Kiel sample set Michigan sample set Combined analysis
Gene Analysis Cases Controls Families1 Cases Controls Families1 Cases Controls Families1
IL-12B rs3212227 359 1,094 57 1,425 1,402 444 1,784 2,496 501
rs6887695 356 1,093 58 1,441 1,422 448 1,797 2,515 506
2-SNP haplotype 355 1,091 57 1,418 1,400 442 1,773 2,491 499
Two locus (with HLA-C) — — — 1,404 1,388 — — — —
IL-23R rs7530511 359 1,093 58 1,444 1,419 451 1,803 2,512 509
rs11209026 359 1,094 58 1,442 1,417 451 1,801 2,511 509
2-SNP haplotype 358 1,090 58 1,440 1,417 451 1,798 2,507 509
Two locus (with HLA-C) — — — 1,424 1,402 — — — —
Total2 All 360 1,097 58 1,450 1,425 451 1,810 2,522 509
FBAT, family-based association test.
1Number of families that are potentially informative for FBAT analysis.
2Total values show the number of individuals or families qualifying for at least of one of the analyses of the study.
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the combined analysis (OR¼1.62 and 1.49, P¼1.71015
and 2.71015, respectively). Lesser but significant associations
were also observed for the IL23R SNPs rs7530511 and
rs11209026 in the combined analysis (OR¼1.22 and 1.40,
P¼0.0039 and 0.00038, respectively). The Kiel and Michigan
samples showed independent evidence for association at both
loci, but the strength and significance of association for IL12B
SNPs was much stronger in the Michigan cohort, whereas for
IL23R SNPs, the Kiel cohort showed stronger association despite
smaller sample size. However, the 95% confidence intervals
overlap when comparing associations between samples, so we
cannot establish a significant difference in genetic effect
between the two populations. For both genes, the risk alleles
were the same as observed previously (Tsunemi et al., 2002;
Capon et al., 2007; Cargill et al., 2007; Chang et al., 2007), with
the more common alleles being the ones that confer risk. For
each SNP, more than 90% of both cases and controls carry at
least one copy of the risk allele. The good fit of the linear trend
model indicates that the mode of inheritance of IL12B and IL23R
is more similar to an additive or multiplicative model than a
recessive or dominant one.
Haplotype case–control association
Results of case–control analysis for two-SNP haplotypes of
each gene are shown in Tables 3 and 4. As reported
previously (Cargill et al., 2007), for both genes the most
common haplotype (AG for IL12B and CG for IL23R) is the
only one of the four observed that is significantly and
positively associated (OR¼ 1.52 and 1.32, P¼1.1 1017
and 1.9106, respectively). The other three IL23R haplo-
types likely have a neutral effect. However, the CC haplotype
for IL12B, which is very strongly negatively associated in
the combined analysis (OR¼ 0.61, P¼ 3.81013), might be
protective, as noted previously (Cargill et al., 2007). The
global linear trend test of association for all haplotypes
combined yielded P-values (2.1109 for IL23R and
4.81017 for IL12B) which exceed any reasonable thre-
sholds for genome-wide significance (Freimer and Sabatti,
2004). Considered individually, both the Michigan and Kiel
samples showed significant association between haplotypes
and disease, which paralleled the results of the combined
analysis. Similar to the single-SNP results, evidence for the
association with the AG haplotype of IL12B is stronger in the
Michigan sample, and evidence for association with the CG
haplotype of IL23R is stronger in the Kiel sample.
Intermarker linkage disequilibrium (LD) is weak for the
two SNPs of the IL23R haplotype in both controls (r2¼0.013
in Kiel and 0.008 in Michigan sample) and cases (r2¼0.003
for both samples). Pairwise LD is somewhat stronger for the
IL12B haplotype (r2¼ 0.25 and 0.24 in controls and 0.22 and
0.23 in cases of the Kiel and Michigan samples). Similar
results were observed for composite LD coefficients (data not
shown), which unlike r2 do not make an implicit assumption
of Hardy–Weinberg equilibrium at the haplotype level. As
expected, when haplotypes are associated with disease, the
LD contrast test using composite coefficients demonstrated
that pairwise LD of the two-SNP haplotypes was significantly
different in cases and controls for both genes—the Kiel,
Table 2. Association of IL-12B and IL-23R SNPs in cases and controls
Kiel sample set Michigan sample set Combined analysis
Frequency in Frequency in
Gene SNP Genotype1 Cases Controls OR (95% CI)2 P3 Cases Controls OR (95% CI)2 P3 OR (95% CI)2 P3
IL12B rs3212227 AA 0.730 0.651
1.42
(1.12–1.80)
0.0029
0.734 0.594
1.69
(1.47–1.94)
7.31014 1.62
(1.43–1.82)
1.7 1015AC 0.254 0.316 0.244 0.346
CC 0.017 0.033 0.023 0.044
rs6887695 GG 0.590 0.510
1.35
(1.12–1.64)
0.0018
0.582 0.452
1.54
(1.37–1.73)
21013 1.49
(1.35–1.64)
2.7 1015GC 0.354 0.393 0.356 0.440
CC 0.056 0.098 0.063 0.109
IL23R rs7530511 CC 0.772 0.715
1.33
(1.04–1.70)
0.023
0.794 0.749
1.17
(1.00–1.38)
0.051 1.22
(1.06–1.39)
0.0039CT 0.212 0.256 0.191 0.218
TT 0.017 0.029 0.015 0.016
rs11209026 GG 0.914 0.856
1.81
(1.22–2.68)
0.0018
0.894 0.867
1.29
(1.03–1.60)
0.023 1.40
(1.16–1.69)
3.8 104GA 0.086 0.138 0.103 0.129
AA 0.000 0.006 0.003 0.004
CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
1For all SNPs, the homozygous risk genotype is given first.
2Odds ratios and their 95% confidence intervals are for the ordinal logistic model, which assumes a constant odds ratio for each additional copy of the risk
allele relative to people carrying one fewer copy.
3Asymptotic P-value for likelihood ratio test of association of psoriasis and genotype using a logistic regression model for linear trend of association.
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Michigan, and combined sample tests yielded P-values of
0.0045, 0.021, and 0.00097 respectively for IL23R, and
0.010, 0.036, and 0.0032 for IL12B. Pairwise LD is lower in
cases than controls, which is predicted by a multiplicative
model with risk alleles of high frequency (Schrodi et al.,
2007). The levels of significance for the LD contrast test are
weaker than those for the ordinary association tests, which
was found by simulation to be generally true when the minor
allele frequencies of the SNPs constituting the haplotype are
low (Wang et al., 2007).
Pedigree analysis
Results obtained using the family-based association test, to
analyze the pedigree sample, are presented in Table 5.
Because family-based association tests are insensitive to
population structure, we pooled the Kiel and Michigan
families (including some non-Caucasian pedigrees) before
analysis. Only the IL12B SNPs yielded significant results
(S*¼0.134 and 0.151, P¼ 0.0022 and 0.0017 for rs3212227
and rs6887695, respectively). However, the trend for both
IL23R SNPs was weakly in the direction of association for the
known risk alleles (S*¼ 0.003 and 0.016 for rs7530511 and
rs11209026, respectively). Haplotype results were similar.
For IL12B, there is moderate evidence for a positive associ-
ation of the AG haplotype (S*¼0.114 and P¼ 0.0021),
a negative association of the CC haplotype (S*¼0.126,
P¼0.0018), and a global association for all haplotypes
combined (P¼ 0.0062). For IL23R, only the CG haplotype
shows any evidence of positive association, albeit nonsignifi-
cant (S*¼ 0.006, P¼ 0.86).
Two-locus analysis
HLA-Cw6 is the best known marker for the major psoriasis
susceptibility locus PSORS1, and is likely to represent the
major disease allele at this locus (Nair et al., 2006). It was
therefore of interest to investigate the effect of including
HLA-Cw6 in the association analysis. In the case–control
sample from Michigan, HLA-Cw6 showed association of
much greater strength (OR¼3.18) and significance
(P¼3.51041) than did the AG risk haplotype of IL12B
(OR¼1.58, P¼ 11015). Including both genes in a two-
locus trend model increases the significance of association
over that seen for either locus alone (P¼2.4 1050), but
does not change the estimated OR of either term, indicating
minimal statistical interaction between the genes. This was
confirmed by a permutational likelihood ratio test comparing
models with and without an interaction term (P¼0.61).
Sample frequencies and ORs for all combinations of risk
diplotypes under a two-locus model without interaction are
shown in Table 6. Results for the joint association of HLA-
Cw6 and the AG risk haplotype of IL23R were similar—there
was no statistical evidence for interaction (P¼ 0.29), and the
Table 3. Association of two-marker haplotypes for the IL12B region in cases and controls
Kiel sample set
Global1 P=0.0082
Michigan sample set
Global1 P=4.81015
Combined analysis
Global1 P=4.81017
Frequency in Frequency in
Diplotype2 Cases Controls OR (95% CI)3 P4 Cases Controls OR (95% CI)3 P4 OR (95% CI)3 P4
AG/AG 0.527 0.447
1.34
(1.12–1.60)
0.0013
0.527 0.384
1.58
(1.42–1.77)
5.7 1016 1.52
(1.38–1.67)
1.1 1017AG/other 0.396 0.426 0.390 0.472
Other/other 0.077 0.127 0.083 0.145
AC/AC 0.028 0.024
0.86
(0.67–1.10)
0.22
0.015 0.031
0.81
(0.70–0.93)
0.0029 0.82
(0.72–0.93)
0.0016AC/other 0.204 0.251 0.237 0.260
Other/other 0.768 0.726 0.748 0.710
CC/CC 0.009 0.017
0.68
(0.52–0.88)
0.0036
0.012 0.026
0.59
(0.51–0.69)
1.5 1011 0.61
(0.53–0.70)
3.8 1013CC/other 0.191 0.255 0.191 0.284
Other/other 0.801 0.727 0.798 0.690
CG/CG 0.000 0.000
0.90
(0.60–1.34)
0.59
0.002 0.002
0.72
(0.57–0.91)
0.0068 0.76
(0.62–0.94)
0.0097CG/other 0.083 0.091 0.071 0.099
Other/other 0.918 0.909 0.927 0.899
CI, confidence interval; OR, odds ratio.
1Global P-value for Wald test of the association of psoriasis and all biallelic diplotypes, calculated using a weighted logistic model for linear trend of
association.
2In each case, the homozygous diplotype for the haplotype being tested is given first; haplotype consists of SNPs rs3212227 and rs6887695.
3Odds ratios and their 95% confidence intervals are for the weighted logistic model for linear trend of association, with a robust variance estimator.
4P-value for Wald test of the association of psoriasis and diplotype, calculated using a weighted logistic model for linear trend of association.
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joint ORs are lower because the genetic effect of the IL23R
risk haplotype in the Michigan sample is lower than that of
IL12B (Table 7).
DISCUSSION
This study confirms an association between psoriasis and
variation in the IL12B and IL23R genes. In agreement with a
previous study (Cargill et al., 2007), a common risk haplotype
was identified for each gene. The global P-values obtained
from haplotype analysis (2.1 109 for IL23R and 4.8
1017 for IL12B) exceed the threshold of 107 recommended
for genome-wide significance (Freimer and Sabatti, 2004).
Although less impressive than the case–control results (a
consequence of smaller sample size), the positive results for
IL12B in the family-based analysis show that the observed
association is not a spurious consequence of population
admixture or stratification. Possibly due to the lesser power of
the IL23R SNPs to detect association (a consequence of the
higher frequency of their risk alleles), the family analysis was
unable to confirm the case–control results for IL23R.
However, there was a weak trend suggesting involvement
of the same IL23R alleles in the family sample (Table 5).
It is interesting that for both IL12B and IL23R, psoriasis was
associated with the more common alleles (that is, the rarer
alleles had a protective effect). In the case of rs3212227 in
IL12B, analysis of 66 chimpanzee chromosomes failed to
identify the G allele, strongly suggesting that the A allele is
ancestral (Hall et al., 2000). This emphasizes the concept that
in complex genetic disorders, the emergence of functional
genetic variants can decrease, as well as increase, disease
susceptibility.
We analyzed association for two-locus models that
include HLA-Cw6, the major identified genetic risk factor
for psoriasis (Nair et al., 2006). We found no statistical
evidence to support the inclusion of an interaction term in
logistic regression analysis of either IL12B (P¼0.61) or IL23R
(P¼0.29). While this finding could be interpreted as a lack of
epistasis between HLA-Cw6 and either IL12B or IL23R, we
note that the term ‘‘epistasis’’ is not well defined biologically
or statistically for polygenic traits, and that lack of statistical
evidence for interaction in logistic regression does not
necessarily imply a lack of biological interaction (Cordell,
2002). Nevertheless, both analyses yielded remarkable
increases in risk between the highest- and lowest-risk
genotype classes (25.3-fold for IL12B and 16-fold for IL23R;
Tables 6 and 7), suggesting that genotyping jointly for
HLA-Cw6, IL12B, and/or IL23R might have diagnostic utility.
While the p40 protein encoded by the IL12B gene is a
component of both IL-12 and IL-23, physiologic studies in
psoriasis, Crohn’s disease, and mouse models of colitis have
identified IL-23 as the p40-containing cytokine most relevant
to disease pathogenesis (Lee et al., 2004; Fuss et al., 2006;
Table 4. Association of two-marker haplotypes for the IL23R gene in cases and controls
Kiel sample set
Global1 P=4.8105
Michigan sample set
Global1 P=1.7104
Combined analysis
Global1 P=2.1 109
Frequency in Frequency in
Diplotype2 Cases Controls OR (95% CI)3 P4 Cases Controls OR (95% CI)3 P4 OR (95% CI)3 P4
CG/CG 0.696 0.587
1.54
(1.24–1.93)
1.3104
0.706 0.646
1.24
(1.09–1.43)
0.0016 1.32
(1.18–1.48)
1.9106CG/other 0.280 0.362 0.265 0.319
Other/other 0.025 0.051 0.030 0.035
TG/TG 0.017 0.029
0.75
(0.58–0.96)
0.022
0.015 0.016
0.85
(0.72–0.99)
0.042 0.82
(0.71–0.93)
0.0028TG/other 0.209 0.255 0.187 0.218
Other/other 0.774 0.716 0.799 0.766
CA/CA 0.000 0.006
0.54
(0.37–0.80)
0.0019
0.003 0.004
0.76
(0.61–0.94)
0.013 0.70
(0.58–0.84)
1.4104CA/other 0.083 0.136 0.099 0.127
Other/other 0.917 0.858 0.899 0.869
TA/TA 0.000 0.000
1.73
(0.59–5.06)
0.31
0.000 0.000
1.60
(0.91–2.81)
0.10 1.63
(0.99–2.70)
0.057TA/other 0.003 0.002 0.004 0.003
Other/other 0.997 0.998 0.996 0.997
CI, confidence interval; OR, odds ratio.
1Global P-value for Wald test of the association of psoriasis and all biallelic diplotypes, calculated using a weighted logistic model for linear trend of
association.
2In each case, the homozygous diplotype for the haplotype being tested is given first; haplotype consists of SNPs rs7530511 and rs11209026.
3Odds ratios and their 95% confidence intervals are for the weighted logistic model for linear trend of association, with a robust variance estimator.
4P-value for Wald test of the association of psoriasis and diplotype, calculated using a weighted logistic model for linear trend of association.
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Yen et al., 2006). IL-23 supports the proliferation and survival
of T-helper 17 cells, a novel subset of CD4þ T cells
characterized by IL-17 production (Steinman, 2007). T-helper
17 cells may play an important role in maintaining chronic
inflammation in psoriasis, Crohn’s disease, and other auto-
inflammatory conditions (Murphy et al., 2003; Iwakura and
Ishigame, 2006; Piskin et al., 2006). Interestingly, a genome-
wide study of Crohn’s disease failed to identify an association
with IL12B (Duerr et al., 2006), whereas psoriasis appears to
be associated with both IL12B and IL23R (Cargill et al., 2007,
and this study). Further studies are required to assess the
statistical and biological significance of these observations.
The fact that common alleles at IL12B and/or IL23R confer
risk for Crohn’s disease, as well as psoriasis, may help to
explain the impressive results of clinical trials targeting the
p40 subunit in both disorders (Mannon et al., 2004; Krueger
et al., 2007). It will be of great interest to explore how
variation in the IL12B and IL23R genes influences clinical
responses of psoriasis and Crohn’s disease to therapies
directed against p40, and how they influence the number
and functional activity of T-helper 17 cells in both disorders.
Our results confirm an association between genes in the IL-
12/IL-23 pathway with psoriasis. They add to a likely genetic
basis for the observed strong clinical association between
Crohn’s disease, psoriasis, and psoriatic arthritis (Rahman
et al., 2003; Ho et al., 2005). Future studies will system-
atically explore genetic commonalities between
inflammatory barrier diseases in general (Schreiber et al.,
2005).
MATERIALS AND METHODS
Subjects
The affected individuals were either identified by the dermatology
services of the University of Michigan Medical Center, the Ann
Arbor Veterans Affairs Medical Center, the University of Kiel, and
Henry Ford Hospital, or provided by the National Psoriasis
Foundation Tissue Bank. Informed consent was obtained from all
subjects under protocols adherent to the Declaration of Helsinki
Principles, and were approved by the Institutional Review Boards of
the participating institutions. Individuals were considered to be
affected if chronic plaque or guttate psoriasis lesions covered more
than 1% of the total body surface area or if at least two skin, scalp,
nail, or joint lesions were clinically diagnosed with psoriasis (Nair
et al., 1997).
The case–control sample included 360 cases and 1,097 controls
from Kiel, as well as 1,450 cases and 1,425 controls from Michigan.
All the cases and controls were of European Caucasian ancestry. The
pedigree sample consisted of 509 pedigrees of various structures,
comprising 2,184 individuals, of whom 1,078 were affected. Fifty-
eight of the families were from Kiel and its vicinity, while the
remainder was from Michigan. All Kiel families and 94% of the
Michigan families were of Caucasian ancestry. Only families in
which the proband age of onset was below 40 years were included
(Henseler and Christophers, 1985). Table 1 shows sample sizes from
each collection center for the various analyses of this study.
Table 5. Association of IL12B and IL23R in families
FBAT1 results
Gene
SNP or
haplotype Allele2 Frequency3 S*4 P5
IL12B rs3212227 A 0.817 0.134 0.0022
rs6887695 G 0.737 0.151 0.0017
rs3212227– AG 0.714 0.114 0.0021
rs6887695 AC 0.124 0.063 0.18
CC 0.119 0.126 0.0018
CG 0.043 0.009 0.90
Multiallelic y — 0.0062
IL23R rs7530511 C 0.865 0.003 0.96
rs11209026 G 0.953 0.016 0.80
rs7530511– CG 0.831 0.006 0.86
rs11209026 TG 0.123 0.004 0.92
CA 0.047 0.009 0.87
TA 0.000 — —
Multiallelic y — 0.98
FBAT, family-based association test; SNP, single-nucleotide polymorphism.
1Family-based association test (Rabinowitz and Laird, 2000; Horvath et al,
2001).
2For single-marker analysis, the known risk allele of each SNP is shown. For
haplotype analysis, all possible alleles are shown.
3Maximum likelihood frequency among all founders in the pedigrees.
4A measure of the strength of association, equal to the mean deviation of
the FBAT test statistic S from its expected value over all families that are
genotypically informative for the test allele.
5All P-values are for biallelic tests, except for the global multiallelic tests of
all haplotype alleles.
Table 6. Association of two-locus risk diplotypes for
HLA-C and IL12B in cases and controls of the
Michigan sample set
No. of copies of Frequency in
HLA-Cw6 IL12B-AG Cases Controls OR (95% CI)1
2 2 0.011 0.003 25.30 (16.62–38.54)
2 1 0.012 0.001 15.98 (11.10–23.01)
2 0 0.004 0.001 10.09 (7.18–14.19)
1 2 0.208 0.065 7.97 (5.94–10.69)
1 1 0.155 0.085 5.03 (4.08–6.21)
1 0 0.030 0.021 3.18 (2.68–3.77)
0 2 0.308 0.317 2.51 (1.99–3.16)
0 1 0.225 0.385 1.58 (1.41–1.78)
0 0 0.049 0.123 1.00 —
CI, confidence interval; OR, odds ratio.
1Odds ratios and their 95% confidence intervals are derived from a two-
locus, weighted logistic regression model for linear trend of association
with no interaction term.
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Genotyping
DNA was prepared from peripheral blood mononuclear cells or
Epstein–Barr virus-immortalized lymphoblastoid cell lines, as pre-
viously described (Nair et al., 1995). SNPs were genotyped by
single-base primer extension as implemented in the SnapShot assay
protocol or by using the TaqMan allelic discrimination method
(Applied Biosystems, Foster City, CA). In addition to the four SNPs
for the IL12B and IL23R genes, seven SNPs in exons 2 and 3 of the
HLA-C gene were also typed, which provide unambiguous HLA-
Cw6 genotypes even in the absence of phasing (Nair et al., 2006).
Genotyping success rates exceeded 98% for all four SNPs in both
sample sets.
Statistical analysis
Deviations of SNP allele frequencies from Hardy–Weinberg equili-
brium were evaluated with an exact test (Wigginton et al., 2005).
Differences in allele frequencies between samples were assessed
with a two-sample t-test.
In cases and controls, logistic regression was used to estimate the
significance of association between single SNPs and disease, along
with ORs and their 95% confidence intervals. SNP genotypes were
modeled as either two nominal variables (analogous to a 2 3
w2-contingency test) or as an ordinal variable with a value of 0, 1, or
2 for the number of copies of the putative risk allele (analogous to the
Cochran–Armitage test for linear trend). A stratum term was included
for combined analysis of the Kiel and Michigan samples. Asymptotic
two-sided P-values for association were obtained by a likelihood
ratio test of appropriately nested models. Likelihood ratio tests were
also used to test for homogeneity of association across sample sets by
including a multiplicative interaction term between genotype(s)
and stratum in the full model. A test for goodness of fit of the linear
trend model was performed by partitioning the statistic of the
likelihood ratio test for the nominal logistic model into its
independent linear trend and fit components (Agresti, 2002).
Because some SNPs have low frequency counts for genotypes
homozygous for the minor allele, asymptotic P-values may not be
reliable, and so significance of association was also assessed by
permutation. Case–control labels were randomly shuffled 10,000
times (shuffling was restricted to within sample stratum for the
combined analysis), and the logistic regression recomputed for each
permutation. For situations where 10 or fewer of the permutational
test statistics exceeded the observed test statistic in magnitude, the
method of moments was used to fit a g-distribution to the set of
10,000 permutation statistics and the permutational P-value
approximated by evaluating its cumulative distribution function.
Association of disease and two-SNP haplotypes for each locus
was tested using weighted logistic regression with a robust
Huber–White variance estimator that was adjusted for correlation
of weights within individuals. Weights in the regression model were
the posterior probabilities of each haplotype pair (diplotype) for each
individual as estimated by version 2.1 of PHASE (Stephens et al.,
2001; Stephens and Donnelly, 2003) with default settings. The use
of diplotype probabilities allows uncertainty in the inference of
haplotypes for doubly heterozygous individuals to be incorporated
into the association analysis. Individuals with missing genotypes for
either of the SNPs at a locus were excluded from analysis, and to
avoid bias haplotypes were estimated separately for cases and
controls within each sample (Cordell, 2006; Mensah et al., 2007).
Although this two-stage procedure does not account for uncertainty
in the probability estimates themselves, it has worked well for both
real and simulated data (French et al., 2006; Mensah et al., 2007).
Each of the four observed two-SNP haplotypes were coded as
biallelic diplotypes and analyzed for association by both the ordinal
and nominal models described before. Coding of the independent
variables for global multi-haplotype trend tests and global multi-
diplotype tests followed that of multiallelic procedures for single
markers (Nielsen and Weir, 1999; Slager and Schaid, 2001; Czika
and Weir, 2004). A stratum variable was used for combined analysis
of both samples. Significance of association was assessed with
asymptotic and permutational univariate or multivariate Wald tests.
Since robust weighted regression is fit with a pseudo-likelihood
function, likelihood ratio tests for homogeneity of association across
samples and for the fit of the linear trend model are no longer
asymptotically distributed as a w2, and so their significance was
assessed by permutation.
Two-locus analysis of HLA-Cw6 genotypes with the two-SNP risk
diplotypes at IL12B or IL23R was carried out for both ordinal and
nominal models, using robust weighted logistic regression. Since
HLA-Cw6 haplotypes could be phased unambiguously, probability
weights in the regression were determined solely by the diplotype
probabilities for IL12B or IL23R. Analysis was restricted to
individuals fully typed for all SNPs constituting the risk haplotypes
at both loci. Interaction between the two loci was modeled by the
appropriate multiplicative term(s). The two-locus ordinal model
without an interaction term was used to estimate ORs and their
confidence intervals for all possible diplotypes for the two loci. All
logistic regression analyses were carried out using Stata statistical
software (Release 9.2; Stata Corporation, College Station, TX; 2006).
Pairwise squared correlation coefficients of LD between the two
SNPs at each locus were calculated separately for cases and controls
in each sample using haplotype frequencies estimated by PHASE.
The LD contrast test (Nielsen et al., 2004) is a novel method that
looks for a difference between cases and controls in the degree of
Table 7. Association of two-locus risk diplotypes for
HLA-C and IL23RB in cases and controls of the
Michigan sample set
No. of copies of Frequency in
HLA-Cw6 IL-23R-CG Cases Controls OR (95% CI)1
2 2 0.020 0.005 16.01 (10.21–25.10)
2 1 0.006 0.000 12.83 (8.85–18.61)
2 0 0.001 0.000 10.29 (7.34–14.42)
1 2 0.271 0.109 4.99 (3.57–6.98)
1 1 0.112 0.057 4.00 (3.20–5.01)
1 0 0.012 0.005 3.21 (2.71–3.80)
0 2 0.415 0.534 1.56 (1.17–2.06)
0 1 0.147 0.261 1.25 (1.08–1.44)
0 0 0.018 0.029 1.00 —
CI, confidence interval; OR, odds ratio.
1Odds ratios and their 95% confidence intervals are derived from a two-
locus, weighted logistic regression model for linear trend of association
with no interaction term.
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pairwise LD between two markers of a haplotype; it is sensitive to a
different pattern of LD than ordinary association tests, and may have
more power in some situations. In its original version, the test
assumes that haplotypes have known phase, and so as suggested by
Zaykin et al. (2006), we extended the test to use unstandardized
composite coefficients of LD (Cockerham and Weir, 1977), with
variances estimated by the formula of Weir (1996), which includes
all higher order (trigenic and quadrigenic) terms. Fisher’s method
was used to combine LD contrast P-values across samples.
Version 1.7.3 of the family-based association test (Rabinowitz
and Laird, 2000; Horvath et al., 2001) was used to analyze the
association of single SNPs and haplotypes in pedigrees. Settings
included an offset of zero, an additive model, and an empirical
variance estimator. Family-based association test properly handles
haplotype phase ambiguity and missing genotypes, while maintain-
ing robustness to population structure (Horvath et al., 2004).
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